Seeking Alpha

Johnson & Johnson (JNJ -3%) proves high-premium buyouts are rare but not altogether dead...

Johnson & Johnson (JNJ -3%) proves high-premium buyouts are rare but not altogether dead with its near-100%-premium acquisition of breast-implant maker Mentor (MNT +89.4%). Counter-trade: Sell Allergan (AGN -8.3%).
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs